The weekend prostate cancer news: Saturday, January 31, 2009

Items covered in this weekend news report include:

  • Acrylamide exposure as a potential risk for prostate cancer
  • The relative merits of three standard first-line therapies in intermediate risk prostate cancer
  • Estramustine + etopside in hormone-refractory prostate cancer (HRPC)
  • Bone turnover markers and risk for skeletal-related events in patients receiving zoledronic acid … READ MORE …

Exercise and radiotherapy: a controlled, randomized trial

It has long been known that external beam radiotherapy for treatment of prostate cancer may cause unfavorable changes in fatigue, quality of life (QOL), and physical fitness. This commentary discusses the results from the Prostate Cancer Radiotherapy and Exercise Versus Normal Treatment study, conducted in Canada. … READ MORE …

Today’s prostate cancer news: Wednesday, October 8

Other than the PCA3 report, additional news today includes:

  • A new review on the combination of EBRT and brachytherapy in localized disease
  • Long-term follow-up data on the use of HIFU at a major German center
  • Early trial data on use of Sutent and Rapamume in men who have failed docetaxel
  • The possible role of pituitary gland surgery in very late stage disease … READ MORE …

ASTRO prostate cancer reports: no. 3

Prostate cancer reports from the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), held in Boston, have kindly been provided by Eyad Abu-Isa, MD, a resident in radiation oncology at the University of Michigan

This year’s scientific sessions concluded on Wednesday with two sessions focused on prostate cancer therapies and long-term outcomes and one afternoon session focused on quality of life outcomes. … READ MORE …